Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 6MHP vaccine + Montanide ISA 51 + Poly ICLC + Varlilumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
6MHP vaccine | 6MHP vaccine is a peptide vaccine containing 6 melanoma helper peptides as epitopes, which may stimulate TH1-biased immune response against tumor cells expressing these antigens (PMID: 25126421, PMID: 26258314). | |||
Montanide ISA 51 | ||||
Poly ICLC | Hiltonol | Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373). | ||
Varlilumab | CDX-1127|CDX127 | CD27 Antibody 3 | Varlilumab (CDX-1127) is an activating monoclonal antibody that binds to CD27 and potentially increases antibody-dependent cellular cytotoxicity towards CD27 positive tumor cells (PMID: 22589397, PMID: 32380537). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03617328 | Phase Ib/II | 6MHP vaccine + Montanide ISA 51 + Poly ICLC + Varlilumab 6MHP vaccine + Montanide ISA 51 + Poly ICLC | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65) | Completed | USA | 0 |